antithrombotic

Guido Parodi, M.D., and colleagues of Careggi Hospital, Florence, Italy, conducted a study to examine whether high residual platelet reactivity (HRPR) after clopidogrel loading (a comparatively large dose of the drug given at the beginning of treatment) is an independent prognostic marker of risk of long-term thrombotic events in patients with acute coronary syndromes (ACS) undergoing an invasive procedure and receiving long-term antithrombotic treatment adjusted according to the results of platelet function tests.

unknown title 2011

SA's Allegra-D 24-hour tablets for treating allergy and a generic version of GlaxoSmithKline's antithrombotic drug Arixtra.

Dr. Reddy's Profit Sinks on Lower North American Sales 2010

Sanofi is an industry leader in the antithrombotic segment and its Lovenox and Plavix anticlotting drugs are forecast to be major growth drivers out to 2012.

Sanofi to Buy Brazil's Medley 2009

Sanofi needs to find new sources of revenue to counter the looming expirations of patents on its two top-selling products, blood-thinner Plavix and antithrombotic Lovenox.

Sanofi Trumps Offer for Zentiva 2008

The French pharmaceuticals giant seems increasingly ill-prepared for the loss of patent protection on its two top-selling drugs -- antithrombotic Lovenox and blood thinner Plavix -- by 2012.

Home-Equity Woes Tarry 2008

HDL reduces growth factor synthesis in the vascular smooth muscle cells, stimulates the production of nitric oxide, modulates endothelial function and is antithrombotic.

Michael R. Eades, M.D.: The Dean Ornish HDL-ain't-nothin-but-a-garbage-truck rag 2006

CHICAGO - Among patients with acute coronary syndromes undergoing a procedure such as angioplasty, those who received platelet function tests before receiving antithrombotic therapy to determine appropriate clopidogrel dosing and who had high residual platelet reactivity platelets resistant to antithrombotic therapy were at an increased risk of an ischemic event at short- and long-term follow-up of up to 2 years, according to a study in the September 21 issue of

unknown title 2011

The Company's current lead product candidates are Exelbine and ANX-514, novel emulsion formulations of currently marketed chemotherapy drugs, and ANX-188, a novel, purified, rheologic and antithrombotic compound initially being developed as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis.

unknown title 2011

"The net clinical outcomes are that patients undergoing elective total knee replacement can benefit from a substantial advancement in the standard of care, and we are potentially a step closer to the unmet need of oral antithrombotic therapy without need for monitoring," wrote Jawed Fareed, MD, of Loyola University in Maywood, Ill., and Russell Hull, MD, of the University of Calgary.

MedPageToday.com - medical news plus CME for physicians 2010

Apixaban, a new antithrombotic agent, is a specific inhibitor of factor Xa in the coagulation cascade.

MedPageToday.com - medical news plus CME for physicians 2010